Novogen (NASDAQ:KZIA) Now Covered by Analysts at Laidlaw

Research analysts at Laidlaw started coverage on shares of Novogen (NASDAQ:KZIA) in a note issued to investors on Wednesday. The brokerage set a “buy” rating and a $25.00 price target on the stock. Laidlaw’s target price indicates a potential upside of 164.27% from the company’s current price.

Several other analysts also recently weighed in on the company. Wall Street Zen downgraded Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Novogen in a report on Wednesday, January 28th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $21.00.

Novogen Price Performance

Shares of NASDAQ:KZIA opened at $9.46 on Wednesday. The company’s 50 day simple moving average is $7.37 and its 200 day simple moving average is $7.79. Novogen has a 1 year low of $2.86 and a 1 year high of $17.40.

Novogen (NASDAQ:KZIA) last released its earnings results on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The business had revenue of $4.89 million during the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.